5:57 PM
 | 
Jan 24, 2013
 |  BC Extra  |  Clinical News

Biogen Idec's pegylated interferon meets in Phase III trial for RRMS

Biogen Idec Inc. (NASDAQ:BIIB) said subcutaneous peginterferon beta-1a given every two or four weeks each met the primary endpoint of reducing annualized relapse rate (ARR) at one year vs....

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >